Key Takeaways
- • S&P Global Ratings estimates that the revised Solvency II framework, effective January 30, 2027, could immediately release up to €80 bn in regulatory capital for European insurers based on existing portfolios, according to Bloomberg.
- • Capital charges on certain long-term equity investments fall to 22%, versus 39% for ordinary listed shares and 49% for most private equity and unlisted holdings, improving the economics of infrastructure, venture capital and energy transition assets for insurers.
- • Blackstone, Apollo Global Management, Pimco and CVC Capital Partners are engaging European insurers on securitized products and private investment-grade credit as the reforms take shape.
- • A preliminary EU securitization agreement would cut risk-weighted floors on qualifying senior tranches to 5% from 10%, against a roughly €1.3 trillion European securitization market at end-June 2026.
- • EIOPA warns that capital relief could weaken solvency buffers and will monitor whether released capital supports strategic objectives rather than shareholder distributions.
Summary
The revised framework reduces capital requirements for certain securitized assets, long-term equity investments and structured credit, with the intent of encouraging insurers to finance infrastructure, defense, digital technology and decarbonization projects across the EU. Charges on some long-term equity investments fall to 22%, compared with 39% for ordinary listed shares and 49% for most private equity and other unlisted holdings. The changes address longstanding criticism that Solvency II imposed disproportionate capital costs on assets suited to insurers' long-term liabilities. Large insurers such as Allianz, AXA and Generali, which use approved internal models, will see a more limited direct effect, while most other European insurers stand to benefit.
Blackstone, Apollo and CVC Capital Partners are discussing the changes with European insurers as they assess opportunities in securitized products and private investment-grade credit. Insurers are showing growing interest in collateralized loan obligations (CLOs) and private investment-grade credit, though adoption is expected to vary and a gradual transition could support healthier market conditions. CVC reports generally positive initial responses from institutions weighing higher allocations. Insurers still face extensive due diligence, transparency and data requirements, along with the need to develop expertise in less-liquid assets.
Alongside the Solvency II amendments, EU policymakers are revising securitization rules to lower bank capital requirements on certain structured credit exposures, with a preliminary agreement cutting risk-weighted floors on senior tranches of qualifying securitizations to 5% from 10%. According to the Association for Financial Markets in Europe, outstanding European securitizations, including CLOs, reached almost €1.3 trillion at the end of June 2026, growing 2.7% year on year but remaining substantially smaller than the US market. Regulators remain cautious given the role of mortgage-backed securities in the 2008 financial crisis.
EIOPA has warned that lower capital requirements could reduce insurers' financial buffers during market stress, and that reported solvency ratios may change only modestly even as capital supporting risks declines. EIOPA will monitor how released capital is used and states it should not primarily finance shareholder distributions or management payments. The European Central Bank has raised similar financial stability concerns as institutions increase private market exposure. CLOs represent roughly 15% of US life insurers' portfolios, while securitizations account for less than 1% of EU insurers' holdings, and US credit markets offer broader opportunities supported by AI infrastructure financing needs.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.